Literature DB >> 26916087

Epb41l3 suppresses esophageal squamous cell carcinoma invasion and inhibits MMP2 and MMP9 expression.

Rong Zeng1, Jun-Peng Huang1, Xu Feng Li1, Wei-Bin Xiong1, Gang Wu1, Zhao-Jing Jiang1, Shu-Jie Song2, Ji-Qiang Li1, Yan-Fang Zheng1, Ji-Ren Zhang1.   

Abstract

EPB41L3 may play a role as a metastasis suppressor by supporting regular arrangements of actin stress fibres and alleviating the increase in cell motility associated with enhanced metastatic potential. Downregulation of epb41l3 has been observed in many cancers, but the role of this gene in esophageal squamous cell carcinoma (ESCC) remains unclear. Our study aimed to determine the effect of epb41l3 on ESCC cell migration and invasion. We investigated epb41l3 protein expression in tumour and non-tumour tissues by immunohistochemical staining. Expression in the non-neoplastic human esophageal cell line Het-1a and four ESCC cell lines - Kyse150, Kyse510, Kyse450 and Caes17 - was assessed by quantitative Polymerase Chain Reaction (qPCR) and Western blotting. Furthermore, an EPB41L3 overexpression plasmid and EPB41L3-specific small interfering RNA were used to upregulate EPB41L3 expression in Kyse150 cells and to downregulate EPB41L3 expression in Kyse450 cells, respectively. Cell migration and invasion were evaluated by wound healing and transwell assays, respectively. The expression levels of p-AKT, matrix metalloproteinase (MMP)2 and MMP9 were evaluated. Expression of epb41l3 was significantly lower in tumour tissues than in non-tumour tissues and in ESCC cell lines compared with the Het-1a cell line. Kyse450 and Caes17 cells exhibited higher expression of epb41l3 than Kyse150 and Kyse510 cells. Overexpressing epb41l3 decreased Kyse150 cell migration and invasion, whereas EPB41L3-specific small interfering RNA silencing increased these functions in Kyse450 cells. Furthermore, overexpressing epb41l3 led to downregulation of MMP2 and MMP9 in Kyse150 and Kyse510 cells. Our findings reveal that EPB41L3 suppresses tumour cell invasion and inhibits MMP2 and MMP9 expression in ESCC cells.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ESCC; Epb41l3; MMP2; MMP9; invasion

Mesh:

Substances:

Year:  2016        PMID: 26916087     DOI: 10.1002/cbf.3170

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  6 in total

1.  Chromium contributes to human bronchial epithelial cell carcinogenesis by activating Gli2 and inhibiting autophagy.

Authors:  Junpeng Huang; Gang Wu; Rong Zeng; Jinting Wang; Rui Cai; James Chung-Man Ho; Jiren Zhang; Yanfang Zheng
Journal:  Toxicol Res (Camb)       Date:  2017-02-15       Impact factor: 3.524

2.  HDAC10 Inhibits Cervical Cancer Progression through Downregulating the HDAC10-microRNA-223-EPB41L3 Axis.

Authors:  Yuan Yuan Gu; Guan Nan Zhou; Yao Li; Hong Yu He; Jing Xin Ding; Ke Qin Hua
Journal:  J Oncol       Date:  2022-01-19       Impact factor: 4.375

3.  TPM3 mediates epithelial-mesenchymal transition in esophageal cancer via MMP2/MMP9.

Authors:  Sui Chen; Zhimin Shen; Lei Gao; Shaobin Yu; Peipei Zhang; Ziyang Han; Mingqiang Kang
Journal:  Ann Transl Med       Date:  2021-08

4.  LINC00052 upregulates EPB41L3 to inhibit migration and invasion of hepatocellular carcinoma by binding miR-452-5p.

Authors:  Liying Zhu; Nenghong Yang; Juan Chen; Tao Zeng; Shaoying Yan; Yuyang Liu; Gangfeng Yu; Qiuxu Chen; Guiqin Du; Wei Pan; Xing Li; Huihao Zhou; Ailong Huang; Hua Tang
Journal:  Oncotarget       Date:  2017-06-29

5.  Silencing EPB41 Gene Expression Leads to Cell Cycle Arrest, Migration Inhibition, and Upregulation of Cell Surface Antigen in DC2.4 Cells.

Authors:  Qing Zhao; Yongqiang Li; Yanhong Li; Xinying Ji; Huimin Li; Dongdong Wu; Wenqiang Wei; Wang Xinchun
Journal:  Med Sci Monit       Date:  2020-03-11

6.  Promoter-associated DNA methylation & expression profiling of genes (FLT 3, EPB41L3 & SFN) in patients with oral squamous cell carcinoma in the Khasi & Jaintia population of Meghalaya, India.

Authors:  Shngainlang Khongsti; Brian Neizekhotuo Shunyu; Srimoyee Ghosh
Journal:  Indian J Med Res       Date:  2019-12       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.